Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

REFERENCES

• Nossov V, Amneus M, Su F, Lang J, Tran-Janco JM, Reddy ST, Farias-Eisner R. The early detection of ovarian cancer: from traditional methods to proteomics: can we really do better than serum CA-125? Am J Obstet & Gynecol 2008;199:215–223.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2010. Atlanta, GA: American Cancer Society, Inc. 2010. Available from: http:// www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__ Figures_2010.asp?from=fast
   Google Scholar
• Zhang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W, Zhong XY. Proteomics and biomarkers for ovarian cancer diagnosis. Annals Clin & Lab Sci 2010;40, 218–225.
   PubMed Web of Science ®Google Scholar
• NCCN & Clinical Resources Web site. NCCN clinical practice guidelines in oncology (NCCN Guidelines), genetic/familial high-risk assessment: breast and ovarian. Heredity breast and/or ovarian cancer, version 1, 2010. Available from: http://www. nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed August 21. 2010.
   Google Scholar
• Hausler SFM, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Honig A, Scheffler M, Dietl J, Wischhusen J. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Brit J Cancer 2010;103, 693–700.
   PubMed Web of Science ®Google Scholar
• Su F, Farias-Eisner R, Reddy S. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomarkers Insights 2007;2, 369–375.
   PubMedGoogle Scholar
• Richter R, Schuz-Knappe P, Schrader M, Standker L, Jurgens M, Tammen H, Forssmann WG. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatog B Biomed Sci Appl 1999;726, 25–35.
   PubMed Web of Science ®Google Scholar
• Hanas JS, Hocker JR, Cheung JY, Larabee JL, Lerner MR, Lightfoot SA, Morgan DL, Denson KD, Prejeant KC, Gusev Y, Smith BJ, Hanas RJ, Postier RG, Brackett DJ. Biomarker identification in human pancreatic cancer sera. Pancreas 2008;36:61–69.
   PubMed Web of Science ®Google Scholar
• Chambers G, Lawrie L, Cash P, Murray GL. Proteomics: a new approach to the study of disease. J Pathol 2000;192:280–288.
   PubMed Web of Science ®Google Scholar
• Verma M, Wright GL Jr, Hanash SM, Gopal-Srivastava R, Srivastava S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Annal NY Acad Sci 2001;945:103–115.
   PubMed Web of Science ®Google Scholar
• West-Norager M, Bro R, Marini F, Hogdall EV, Hogdall CK, Nedergaard L, Heegaard NH. Feasibility of serodiagnosis of ovarian cancer by mass spectrometry. Anal Chemist 2009;81:1907–1913.
   PubMed Web of Science ®Google Scholar
• Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271–284.
   PubMed Web of Science ®Google Scholar
• Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102–112.
   PubMed Web of Science ®Google Scholar
• Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformat 2003;4:24.
   PubMed Web of Science ®Google Scholar
• Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005;51:3–5.
   PubMed Web of Science ®Google Scholar
• Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005;5:1–7.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;481:296–304.
   Google Scholar
• Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, Zhang WH, Peng CH, Zhang SD, Li HW, Chen GQ. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncol 2005;68:79–86.
   Google Scholar
• Hocker JR, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Quillet A, Hanas RJ, Peyton MD, Postier RG, Brackett DJ, Hanas JS. Distinguishing early clinical stages of pancreatic cancer using Serum profiling. Cancer Invest 2011;29:173–179.
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309–314.
   PubMed Web of Science ®Google Scholar
• Guan W, Zhou M, Hampton CY, Benigno BB, Walker LD, Gray A, McDonald JF, Fernández FM. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinformatics 2009;10:259–274.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind C. International Union against Cancer; TNM: Classification of Malignant Tumors, 6th edition. New York, NY: Wiley-Liss, 2002.
   Google Scholar
• Altman DG, Bland M. Statistics notes: diagnostic tests 2: predictive values. Brit Med J 1994;309:102.
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland M. Statistics notes: diagnostic tests 1: sensitivity and specificity. Brit Med J 1994;308:1552.
   Google Scholar
• National Committee for Clinical Laboratory Standards. User evaluation of precision performance of clinical chemistry devices. NCCLS Tentative Guideline EP5-T 2004.
   Google Scholar
• Postier RG, Lerner MR, Lightfoot SA, Vannarath R, Lane MM, Hanas JS, Brackett DJ. DNA ploidy and markovian analysis of neoplastic progression in experimental pancreatic cancer. J Histochem Cytochem 2003;51:303–309.
   PubMed Web of Science ®Google Scholar
• Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:1749–1760.
   Web of Science ®Google Scholar
• Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clinic Proceed. 2010;85:1111–1120.
   PubMed Web of Science ®Google Scholar
• Hocker JR, Peyton MD, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Bates-Albers LM, Vu NT, Hanas RJ, Kupiec TC, Brackett DJ, Hanas JS. Serum profiling of stage I/II lung cancer patients using electrospray ionization mass spectrometry. Lung Cancer 2011;74:206–211.
   PubMed Web of Science ®Google Scholar